Genetics drives a new stage in precision preventive medicine
The integration of polygenic risk models based on genome-wide association studies (GWAS) enables healthcare professionals to incorporate genetic risk stratification into clinical practice and advance toward data-driven, personalized prevention.
Traditional healthcare models have primarily focused on diagnosis and treatment after disease onset. The consolidation of large-scale genome-wide association studies (GWAS) and the development of polygenic risk scores (PRS) are enabling a structural shift toward predictive medicine, where genetic predisposition can be incorporated as an early risk stratification tool.
Polygenic models, built through the weighted aggregation of variants identified in GWAS, allow the estimation of individual risk for complex diseases and relevant metabolic domains. When interpreted within the appropriate clinical context, this information becomes a decision-support instrument for healthcare professionals.
In this context, N-GENE has developed a platform designed exclusively for healthcare professionals that translates genomic evidence into clinically interpretable algorithms. The system categorizes risk across areas such as lipid metabolism, glycemic profile, systemic inflammation, cardiovascular health, and aging-related biological processes, facilitating the prioritization of individualized preventive interventions.
Genetics does not replace conventional clinical assessment; rather, it adds a stable layer of biological information that enhances preventive precision. This approach enables professionals to offer patients personalized strategies in nutrition and lifestyle interventions, strengthening healthcare efficiency and reinforcing the role of Spanish biotechnology in evidence-based prevention.